In the latest clinical guidelines, dupilumab—a monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα)—has been approved as an anti-inflammatory treatment for a select subgroup of patients with eosinophilic chronic obstructive pulmonary disease (COPD) (48). Here, IL4R is linked to chronic obstructive pulmonary disease.